HWM
KROS icon

HighMark Wealth Management’s Keros Therapeutics KROS Stock Holding History

HighMark Wealth Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75
Closed -$3.43K – 610
2024
Q2 		$3.43K Hold
75
– – ﹤0.01% 420
2024
Q1 		$4.96K Hold
75
– – ﹤0.01% 375
2023
Q4 		$2.98K Hold
75
– – ﹤0.01% 429
2023
Q3 		$2.39K Hold
75
– – ﹤0.01% 435
2023
Q2 		$3.01K Buy
+75
New +$3.29K ﹤0.01% 415
2021
Q4 		– Sell
-148
Closed -$3K – 514
2021
Q3 		$3K Buy
+148
New +$5.27K ﹤0.01% 419

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

HighMark Wealth Management's KROS Position: Q3 2024 in Review

HighMark Wealth Management sold out of Keros Therapeutics (KROS) in Q3 2024, closing a stake of 75 shares — an estimated $3.43K sold.

HighMark Wealth Management first reported a position in KROS in Q3 2021 and held it in 6 quarters. The position peaked at $4.96K in Q1 2024. 163 funds tracked by Wall St. Rank hold KROS as of Q3 2024.

  • HighMark Wealth Management reported no remaining Keros Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HighMark Wealth Management sold 75 Keros Therapeutics shares in Q3 2024, an estimated $3.43K.
  • HighMark Wealth Management first reported a position in Keros Therapeutics in Q3 2021 and held it in 6 quarters.
  • HighMark Wealth Management's Keros Therapeutics position peaked at $4.96K in Q1 2024.
  • 163 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2024.

Based on HighMark Wealth Management's 13F filing for Q3 2024, filed 17 Oct 2024.